UK – MHRA regulatory flexibilities resulting from coronavirus (COVID-19)

Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.

We are working closely with the Department of Health and Social Care (DHSC) and other healthcare partners and stakeholders to rapidly develop a package of ‘flexibilities’ to regulatory guidance, in order to support the medicines supply chain and wider healthcare response to the COVID-19 outbreak in the UK.

These regulatory flexibilities are:

  • temporary and will be kept under review, except where regulatory extensions have been stated
  • offered to provide flexibility in exceptional circumstances
  • effective immediately…